NeuSpera Medical said it snagged the former R&D senior vice president at Cyberonics, Milton Morris, for its corner office as it gears up to raise a Series A round for its neuromodulation technology.
NeuSpera, formerly known as Vivonda Medical, is developing injectable neuromodulation devices, so called “electroceuticals,” using licensed mid-field powering technology. The Santa Clara, Calif.-based company says its implantable module is 100 times smaller than other neuromodulation devices. NeuSpera said it’s raised more than $1 million in angel funding so far.
“We are delighted to welcome Milton as NeuSpera’s president & CEO,” NeuSpera chairman Bing Yeh said in prepared remarks. “Bringing with him over 23 years of rich experience in the medical device industry, Milton is a dynamic leader and a talented executive with a proven track record of driving technology innovation and business growth. For the past several months, Milton has been working with the company as a consultant. Under his guidance, the team has made great progress and is now ready to take the next step in addressing the milestones targeted for Series A financing. I am confident that Milton has the leadership qualities and industry experience to propel NeuSpera forward.”
“I am excited to be leading NeuSpera Medical – a young, fast-moving company with a truly innovative technology,” added Morris, who was already a member of the company’s board. “It is a privilege to be in a position to positively impact human lives through medical technology – a privilege that I take seriously. NeuSpera has the opportunity to fundamentally change the way neuromodulation therapy is delivered. I look forward to realizing its great potential.”
NuVasive taps Thermo Fisher’s Lai for IT chief
NuVasive Inc. (NSDQ:NUVA)
said it lured Thermo Fisher‘s (NYSE:TMO) vice president of IT, Johnson Lai, to be its new chief information officer.
Read more
Check-Cap promotes Densel to CEO
Check-Cap (NSDQ:CHEK) said it named Bill Densel to replace Guy Neev as CEO. Densel was the company’s U.S. operations president. Neev is slated to stay on as a consultant through the end of 2015.
Read more
Bone Biologics grabs La Neve for CEO, Frelick for COO
Bone Biologics said it named medtech veteran Stephen La Neve to be its new CEO, replacing interim chief Michael Schuler, and tapped Jeffrey Frelick to be its COO.
Read more
Nephros names former Outset Medical CEO Pinto to board
Nephros (OTC:NEPH) said it named Moshe Pinto, the former CEO of Home Dialysis Plus (now Outset Medical) to its board of directors.
Read more
